OP-1 trial under way:
This article was originally published in Clinica
Stryker (US) has completed patient recruitment in its OP-1 fracture healing trial. Creative BioMolecules, developer of the OP-1 morphogenic protein, says most patients have already been treated. An undisclosed number of patients will be followed for nine months to see whether OP-1 performs better than bone chips in non-union fractures.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.